VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Analyst Ratings Published 06/17/2025, 11:02 AM 0 Vertex stock price target lowered to $420 on slower Alyftrek uptake VRTX 0.57% ...

The stock's fall snapped a three-day winning streak.

A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Vertex’s financial performance remains strong, with the company recently raising its 2025 revenue guidance to $11.85-$12.0 billion, up from the previous range of $11.75-$12.0 billion.